US panel review for Seroquel XR in depression and anxiety
This article was originally published in Scrip
Executive Summary
The US FDA's psychopharmacologic drugs advisory panel is tentatively scheduled to review AstraZeneca's supplemental NDAs for Seroquel XR (quetiapine fumarate extended-release) in major depressive disorder and generalised anxiety disorder (GAD) on April 8th, the company said.